Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIV Protease Inhibitors for PAH
NCT02023450Phase 1Unknown
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Dec 2013
- Primary completion
- Dec 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of saquinavir in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: High Mobility Group Box 1 Protein Level at 14 days. Status: unknown.
02
Drugs
saquinavir
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT02023450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02023450.